Published in J Pediatr on February 01, 1984
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev (1991) 7.12
The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev (2010) 4.22
DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia isolates from a nosocomial outbreak. J Clin Microbiol (1991) 4.20
Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol (2001) 4.12
Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol (2001) 4.02
Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax (2004) 3.25
Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol (1985) 3.09
Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol (1996) 2.95
Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol (1999) 2.87
Quorum sensing in Burkholderia cepacia: identification of the LuxRI homologs CepRI. J Bacteriol (1999) 2.81
Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol (1994) 2.74
The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol (2008) 2.71
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 2.60
Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J Clin Microbiol (1987) 2.59
Infection control in cystic fibrosis. Clin Microbiol Rev (2004) 2.45
Common features of environmental and potentially beneficial plant-associated Burkholderia. Microb Ecol (2011) 2.44
Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health? Emerg Infect Dis (1998) 2.43
Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol (1987) 2.31
Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis (2002) 2.26
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Subgrouping of Pseudomonas cepacia by cellular fatty acid composition. J Clin Microbiol (1989) 2.23
Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex. J Clin Microbiol (2002) 2.16
Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol (1993) 2.12
Construction and evaluation of plasmid vectors optimized for constitutive and regulated gene expression in Burkholderia cepacia complex isolates. Appl Environ Microbiol (2002) 2.07
Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol (2001) 2.06
Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients. J Clin Microbiol (2000) 1.91
Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis (2010) 1.84
Production and utilization of pyochelin by clinical isolates of Pseudomonas cepacia. J Clin Microbiol (1986) 1.82
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.80
Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol (1995) 1.79
Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax (1995) 1.78
Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother (1996) 1.76
Invasion and intracellular survival of Burkholderia cepacia. Infect Immun (2000) 1.74
Influence of Pseudomonas aeruginosa exoproducts on virulence factor production in Burkholderia cepacia: evidence of interspecies communication. J Bacteriol (1995) 1.74
Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia. Infect Immun (1990) 1.73
Purification and characterization of an extracellular protease from Pseudomonas cepacia. Infect Immun (1989) 1.70
Advances in electronic-nose technologies developed for biomedical applications. Sensors (Basel) (2011) 1.66
A novel sensor kinase-response regulator hybrid controls biofilm formation and type VI secretion system activity in Burkholderia cenocepacia. Infect Immun (2008) 1.64
An epidemic of burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis (1999) 1.59
Identification of Burkholderia cenocepacia genes required for bacterial survival in vivo. Infect Immun (2004) 1.57
Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child (1990) 1.55
Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect Immun (2008) 1.55
Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein. Antimicrob Agents Chemother (1992) 1.50
Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol (1991) 1.50
Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis. J Clin Microbiol (1998) 1.50
Regulation of ornibactin biosynthesis and N-acyl-L-homoserine lactone production by CepR in Burkholderia cepacia. J Bacteriol (2001) 1.49
Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun (1998) 1.47
A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J Bacteriol (2006) 1.46
Role of flagella in host cell invasion by Burkholderia cepacia. Infect Immun (2002) 1.46
Microbiology of cystic fibrosis lung infections: themes and issues. J R Soc Med (1993) 1.46
Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis. J Clin Microbiol (1993) 1.45
Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products. Infect Immun (1997) 1.44
Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia genomovars I, III, and IV by PCR. J Clin Microbiol (1999) 1.43
Culture-independent analysis of bacterial diversity in a child-care facility. BMC Microbiol (2007) 1.42
Typing of Pseudomonas cepacia by bacteriocin susceptibility and production. J Clin Microbiol (1985) 1.40
Burkholderia cepacia genomovar III Is a common plant-associated bacterium. Appl Environ Microbiol (2001) 1.39
Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources. J Clin Microbiol (1988) 1.37
Identification of the mucin-binding adhesin of Pseudomonas cepacia isolated from patients with cystic fibrosis. Infect Immun (1992) 1.35
Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections. J Clin Microbiol (2004) 1.33
Development of a PCR probe test for identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia. J Clin Pathol (1994) 1.33
Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex. J Bacteriol (2002) 1.32
Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child (1992) 1.31
Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiol (2009) 1.30
Identification of a novel virulence factor in Burkholderia cenocepacia H111 required for efficient slow killing of Caenorhabditis elegans. Infect Immun (2004) 1.30
Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis (2010) 1.29
Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers. J Clin Microbiol (1997) 1.29
Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax (1996) 1.29
Characterization of hemolysin in extracellular products of Pseudomonas cepacia. J Clin Microbiol (1987) 1.28
Identification of specific and universal virulence factors in Burkholderia cenocepacia strains by using multiple infection hosts. Infect Immun (2009) 1.27
Production of lipase by clinical isolates of Pseudomonas cepacia. J Clin Microbiol (1988) 1.25
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother (2006) 1.24
Distribution of quorum-sensing genes in the Burkholderia cepacia complex. Infect Immun (2001) 1.23
Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol (2003) 1.23
Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation. Infect Immun (2004) 1.22
A decade of Burkholderia cenocepacia virulence determinant research. Infect Immun (2010) 1.22
The mgtC gene of Burkholderia cenocepacia is required for growth under magnesium limitation conditions and intracellular survival in macrophages. Infect Immun (2006) 1.22
Burkholderia cenocepacia ZmpB is a broad-specificity zinc metalloprotease involved in virulence. Infect Immun (2006) 1.22
Identification of members of the Burkholderia cepacia complex by species-specific PCR. J Clin Microbiol (2000) 1.21
Patterns of epithelial cell invasion by different species of the Burkholderia cepacia complex in well-differentiated human airway epithelia. Infect Immun (2002) 1.21
Reconstitution of O-specific lipopolysaccharide expression in Burkholderia cenocepacia strain J2315, which is associated with transmissible infections in patients with cystic fibrosis. J Bacteriol (2005) 1.20
Invasion of spores of the arbuscular mycorrhizal fungus Gigaspora decipiens by Burkholderia spp. Appl Environ Microbiol (2003) 1.20
Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother (1988) 1.20
Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice. Infect Immun (2001) 1.19
Burkholderia cepacia respiratory tract acquisition: epidemiology and molecular characterization of a large nosocomial outbreak. Epidemiol Infect (1996) 1.18
Identification of IS1356, a new insertion sequence, and its association with IS402 in epidemic strains of Burkholderia cepacia infecting cystic fibrosis patients. J Clin Microbiol (1996) 1.16
Attenuated virulence of a Burkholderia cepacia type III secretion mutant in a murine model of infection. Infect Immun (2003) 1.15
In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother (1993) 1.15
Construction of aminoglycoside-sensitive Burkholderia cenocepacia strains for use in studies of intracellular bacteria with the gentamicin protection assay. Appl Environ Microbiol (2010) 1.14
Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability. Antimicrob Agents Chemother (1989) 1.14
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection. Infect Immun (2002) 1.13
Quorum-sensing mutations affect attachment and stability of Burkholderia cenocepacia biofilms. Appl Environ Microbiol (2005) 1.13
Burkholderia cenocepacia C5424 produces a pigment with antioxidant properties using a homogentisate intermediate. J Bacteriol (2007) 1.13
Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. J R Soc Med (1986) 1.12
Structural and functional characterization of diffusible signal factor family quorum-sensing signals produced by members of the Burkholderia cepacia complex. Appl Environ Microbiol (2010) 1.12
Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center. Eur J Clin Microbiol Infect Dis (2008) 1.12
Quorum-sensing signals and quorum-sensing genes in Burkholderia vietnamiensis. J Bacteriol (2002) 1.11
Burkholderia cepacia Complex: Emerging Multihost Pathogens Equipped with a Wide Range of Virulence Factors and Determinants. Int J Microbiol (2010) 1.11
Molecular typing and exopolysaccharide biosynthesis of Burkholderia cepacia isolates from a Portuguese cystic fibrosis center. J Clin Microbiol (2000) 1.11
High-temperature-induced transposition of insertion elements in burkholderia multivorans ATCC 17616. Appl Environ Microbiol (2005) 1.10
Management of asthma: a consensus statement. Arch Dis Child (1989) 7.04
Plastic mattresses and sudden infant death syndrome. Lancet (1995) 5.59
Prediction of mortality in patients with cystic fibrosis. N Engl J Med (1992) 5.46
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med (1990) 4.70
A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol (1988) 4.41
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Sudden unexplained infant death in 20 regions in Europe: case control study. Lancet (2004) 3.60
Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr (1997) 3.38
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Bronchial reactivity in cystic fibrosis. Pediatrics (1978) 2.70
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature (1997) 2.63
Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr (1988) 2.62
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
Acceptance of repeat population-based voluntary counselling and testing for HIV in rural Malawi. Sex Transm Infect (2008) 2.59
Standards of pulmonary function in children. Am Rev Respir Dis (1969) 2.56
The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med (1995) 2.49
Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet (1992) 2.48
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics. J Pediatr (1981) 2.41
Pulmonary function abnormalities in symptom-free children after bronchiolitis. Pediatrics (1977) 2.32
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med (1984) 2.22
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet (1987) 2.05
Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis (1976) 2.03
Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial. N Engl J Med (1973) 2.00
Pulmonary function and bronchial hyperreactivity in long-term survivors of bronchopulmonary dysplasia. Pediatrics (1981) 2.00
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Ultrastructure of airways in children with asthma. Histopathology (1978) 1.97
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.97
A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr (2000) 1.93
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.80
Hepatic abscess and cystic fibrosis. Postgrad Med J (1988) 1.77
Role of conventional physiotherapy in cystic fibrosis. J Pediatr (1988) 1.75
Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology (1988) 1.75
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.73
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
A study of bereavement care after a sudden and unexpected death. Arch Dis Child (1996) 1.70
Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr (1995) 1.70
The HIV information project for transfusion recipients a decade after transfusion. Arch Pediatr Adolesc Med (1995) 1.70
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet (1989) 1.66
Diabetes mellitus in patients with cystic fibrosis: effect on survival. Pediatrics (1990) 1.65
Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis. J Pediatr (2005) 1.64
Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr (1982) 1.64
Increased incidence of bronchial reactivity in children with a history of bronchiolitis. J Pediatr (1981) 1.62
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Clinical and physiological assessment of asthmatic children treated with beclomethasone dipropionate. J Allergy Clin Immunol (1976) 1.59
Transit time analysis of the forced expiratory vital capacity in cystic fibrosis. Am Rev Respir Dis (1976) 1.58
Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry (1980) 1.58
Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr (1995) 1.56
Severe acute asthma in a pediatric intensive care unit: six years' experience. Pediatrics (1989) 1.54
Volume of isoflow. A new test in detection of mild abnormalities of lung mechanics. Am Rev Respir Dis (1974) 1.53
Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med (1985) 1.52
Pulmonary function in children with asthma at acute attack and symptom-free status. Am Rev Respir Dis (1969) 1.52
The approach to chronic cough in childhood. Ann Allergy (1988) 1.51
Energy expenditure of patients with cystic fibrosis. J Pediatr (1987) 1.51
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Mucociliary tracheal transport rates in man. J Appl Physiol (1975) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene? Clin Genet (2009) 1.47
CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet (1995) 1.47
Shwachman syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. J Pediatr (1999) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Lung function in children following repair of tracheoesophageal fistula. J Pediatr (1979) 1.46
Airway closure in children. J Appl Physiol (1972) 1.45
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut (2003) 1.45
Hypoalbuminemia at initial examination in patients with cystic fibrosis. J Pediatr (1989) 1.45
The oral cavity in Crohn's disease. J Pediatr (2001) 1.44
Childhood asthma: a rational approach to treatment. Ann Allergy (1990) 1.44
A case report of pre-eruptive coronal resorption in a mandibular canine. Dent Update (1999) 1.43